IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT01737398
- Locations
- 🇵🇹
CHP-HGSA, Unidade Clinica de Paramiloidose, Porto, Portugal
🇩🇪UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin, Munster, Germany
🇪🇸Hospital Universitari Vall D' Hebron, Barcelona, Spain
Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT01713361
- Locations
- 🇺🇦
Isis Investigational Site, Sevastopol, Ukraine
Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01710852
- Locations
- 🇬🇧
Eastbourne General Hospital - Cardiology Department, Eastbourne, East Sussex, United Kingdom
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01647308
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01563302
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT01529424
- Locations
- 🇺🇸
Physicians East, Quadrangle Medical Specialists, Greenville, North Carolina, United States
🇺🇸Eastern Carolina Physicians, Kinston, North Carolina, United States
🇺🇸Natalie A Doyle, MD PA, Wilson, North Carolina, United States
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01414101
- Locations
- 🇷🇺
Isis Investigational Site, Saint Petersburg, Russian Federation
🇨🇦Isis Investigational site, Kamloops, British Columbia, Canada
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT01234038
- Locations
- 🇵🇱
Alojzy Pawelec Provincial Hospital of Lung Diseases, Wodzislaw Slaski, Poland
🇭🇺Semmelweis University Faculty of Medicine, Budapest, Hungary
🇵🇱Independent Public Teaching Hospital No. 4 In Lublin, Lublin, Poland
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT01234025
- Locations
- 🇺🇸
Fort Range Cancer Center, Fort Collins, Colorado, United States
🇺🇸St. Luke's - Roosevelt Hospital Center, New York, New York, United States
🇵🇱Clinical Oncology Department and Day Hospitalization Unit, Independent Public Healthcare Facility T. Koszarowski Opolskie Oncology Centre in Opole, Opole, Poland
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
- First Posted Date
- 2009-12-31
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT01041222
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Methodist Neurological Institute, Houston, Texas, United States